Skip to Content

Chemotherapy Might Not Be Needed in Frontline Treatment of Patients with Large B-Cell Lymphoma

The Smart Stop abstract examines the combination of lenalidomide, tafasitamab, rituximab, and acalabrutinib in patients with newly diagnosed diffuse large B-cell lymphoma. Dr. Jason Westin discusses in this MEDtalk if targeted therapy can reduce or even eliminate the need for chemotherapy in these patients. Initial findings show a 63% complete response rate and a 100% overall response rate after four cycles of treatment.

Jason Westin

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top